Article Figures & Data
Figures
- Fig 1.
Number of lung cancer diagnoses over the past 7 years.
- Fig 2.
Comparison of (a) source of referrals, (b) setting of first review, (c) lung cancer histological type, and (d) World Health Organization (WHO) staging during the pre-Coronavirus 2019 (COVID-19) versus COVID-19 time period. *p<0.05; **p<0.005; ***p<0.0005. 2WW = 2-week wait; A&E = accident and emergency; MDT = multidisciplinary team; NOS = not otherwise specified; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer.
- Fig 3.
Lung cancer treatment approach and strategy. BSC = best supportive care; COVID-19 = Coronavirus 2019.
Tables
Patient demographics Pre-COVID-19 (n=228) During COVID-19 (n=196) Post COVID-19–2021 (n=244) p-value Gender (%) Male 50.6 47.7 49.5 0.373 Age/years (mean; range) 73 (65–81) 75 (68–82) 69 (62–76) 0.165 WHO performance score (mean; range) 2 (1–3) 2 (1–3) 2 (1–3) 0.02 Source of referral (%) MDT 31.3 25.4 30.5 0.381 2WW 46.3 36.3 44.7 <0.0001 Inpatient 22.4 33.2 24.8 0.00374 Unknown 0 5.18 0 <0.0001 Setting of first review (%) A&E 0 1.04 2.05 0.0937 Hospital acute unit 15 7.78 9.1 0.1936 Hospital ward 40.9 46.6 42.3 0.0432 OPD 49.2 34.2 45.6 0.0551 Telephone 8.29 5.7 0.95 0.0064 Unknown 0 4.15 0 <0.0001 2WW = 2-week wait referral; A&E = accident and emergency; COVID-19 = Coronavirus 2019; MDT = multidisciplinary team; OPD = outpatient department; WHO = World Health Organization.
- Table 2.
Histology and staging of patients with lung cancer at presentation before, during and after the COVID-19 pandemic
Disease characteristics Pre-COVID-19 (%) (n=228) During COVID-19 (%) (n=196) Post COVID-19–2021 (%) (n=244) p-value Histology SCLC 9.69 8.29 8.7 0.865 NSCLC squamous 27.8 12.4 26.9 0.0002 NSCLC adenocarcinoma 37 40.9 39.4 0.706 NSCLC NOS 0 1.55 1.8 0.159 No histology 25.6 34.7 23.2 0.0226 TNM classification T1 17.5 17.1 17.3 0.997 T2 16.5 19.8 17.8 0.684 T3 22.2 19.3 21.3 0.765 T4 43.9 41.7 42.4 0.954 Tx 0 2.08 1.2 0.124 N0 31.1 32.1 30.3 0.908 N1 7.55 11.5 8.2 0.339 N2 23.6 32.2 25.6 0.193 N3 37.3 25 35.9 0.0157 Nx 0.472 0 0 0.357 M0 46.7 50 49.3 0.783 M1 53.3 50 50.7 0.783 WHO staging I 14.5 17.2 18.3 0.519 II 7.94 8.3 7.8 0.978 III 27.1 24.5 25.6 0.827 IV 50.5 50 48.3 0.893 NOS = not otherwise specified; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; TNM = classification of malignant tumours; WHO = World Health Organization.
- Table 3.
Treatment approach to lung cancer before, during and after the COVID-19 pandemic
Treatment approach/category Pre-COVID-19 (%) (n=227) During COVID-19 (%) (n=193) Post COVID-19–2021 (%) (n=244) p-value Treatment approach Curative 19.8 23.5 21.3 0.646 Palliative 80.2 76.5 78.7 0.646 Treatment category Chemotherapy 32.9 23 26.1 0.0625 Radiotherapy 5.26 2.04 3.8 0.217 Chemoradiotherapy 0 2.55 0.7 0.0332 Surgery 18 20.9 24.2 0.256 BSC 43.9 51.5 45.2 0.243 BSC = best supportive care; COVID-19 = Coronavirus 2019.
Jump to section
Related Articles
Cited By...
- No citing articles found.